20.09.2012: BIND Biosciences appoints industry veteran Dan Lynch as Chairman of the Board of Directors. Dan Lynch brings more than 25 years of experience serving in management and board positions in the biotechnology and pharmaceutical industries. Dan spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, he led ImClone through a significant turnaround, including securing FDA approval of ERBITUX® (Cetuximab), an important new cancer treatment.

Press Release